Blog

DENVER, CO / ACCESS Newswire / November 20, 2025 / In a society that rarely talks about the quiet devastation addiction brings to a marriage, Katie and Chris Bowick offer something rare: a brave, two-voice memoir that reveals the hidden truths, the painful regrets, and the unexpected redemption born from choosing to heal.

Coloring Outside the Lines: A Love Story in the Gray of Addiction, Recovery, and Redemption is a gripping, dual-perspective account of the Bowicks’ journey through addiction, codependency, trauma, and, ultimately, healing. Told in two raw and unforgettable voices, their story weaves together pain and perseverance, heartbreak and grace, and the surprising pathways that lead toward hope.

Chris, a charismatic, witty, and accomplished entrepreneur, breaks many stereotypes about what many believe addiction should look like. His outward success masked profound internal pain: unhealed childhood trauma, loss, grief, and ultimately, full-blown addiction. Katie’s story is equally compelling. Caught between love and impossible choices, she became the keeper of secrets, manager of chaos, and tireless advocate for a life that seemed to be slipping away. Her resilience was fueled by her faith and a deep belief in the quiet beauty that exists in both the people and world around her. Even in their darkest moments, she held on to the hope that healing, for both of them, was still possible.

Coloring Outside the Lines quickly climbed the charts, becoming a #1 New Release in five categories, including Substance Abuse Recovery and Psychological Pathologies, and earning the #2 bestseller spots in Codependency, as well as Drug Dependency & Recovery. The book’s striking cover was designed by Rich Johnson of Spectacle Photography, with photography by Angelli Nguyen and creative direction by Samantha Joy.

The Bowicks’ unique experience navigating addiction led them to many forms of recovery. What they found was that many traditional models for addiction rehab did not work for their lived experience. Eager to help Chris get to the other side of addiction, they began to seek alternative forms of rehab and therapy.

“We want to change how people see addiction. It’s not a character flaw or a moral failure. It’s something that touches us all, and the sooner we stop treating people like villains, the sooner real healing can begin.” – Chris Bowick

Together, the Bowicks pull back the curtain on the often-invisible toll of addiction. Despite deep diving into the realities of addiction, Coloring Outside the Lines is not simply a story of struggle; it is a story of rebuilding and reckoning, of choosing healing not just through traditional recovery models, but also through plant and animal medicine, therapy, faith, and deep self-exploration.

Katie and Chris Bowick, beautifully photographed by their wedding photographer, Steve Stanton.

At its heart, the book is about love. Not the romanticized version, but the unflinching, gritty kind. The kind that shows up at 3 a.m., forgives without forgetting, holds space without enabling, and learns to set boundaries without abandoning the heart.

“We stopped trying to fit our healing inside the lines and started coloring with every shade to get out of the gray. Loving someone through addiction means living in that in-between space, where hope and heartbreak collide. I had to learn that healing wasn’t just his journey. It was mine too.” – Katie Bowick

Coloring Outside the Lines is a mirror for anyone who has ever loved someone battling addiction or has ever lost themselves in the process. Through raw storytelling and dual perspectives, readers witness the collapse of a marriage and the painstaking reconstruction that follows.

Addiction is messy, but so is healing, and I think we forget that sometimes. This book takes you through every emotion but ultimately leaves you with a deeper understanding of what addiction is, what an addict endures, and how they can come out the other side, and the kind of support it truly takes to get there – Ashley P.

Published by Landon Hail Press, this memoir offers readers both the heartbreak and the hope that come with rebuilding a life touched by trauma, relapse, boundaries, recovery, and the radical relearning of unconditional love. Dedicated to creating a sacred and transparent space for writers, Landon Hail Press allows authors to own the creative direction of their book and their brand. LHP books have been sold on Amazon, Barnes & Noble, bookshop.org, and more, and featured in major publications like The Daily Mail and People.com.

“Katie and Chris do what most substance abuse programs do not, highlighting the bonds that are forged (and broken) in the storm of active addiction and recovery, giving the reader reference points for every step of the journey. It includes the partner’s perspective of what it’s like to love an addict and the emptiness it brings, being out of the spotlight, cast away in the darkness,” says Samantha Joy, Editor-in-Chief at Landon Hail Press. “Their stories emphasize how nonlinear this process is, and that overcoming addiction in its simplest form is making the conscious choice to come back home to yourself and each other again and again.”

Are you an aspiring author? Book a free consultation with Landon Hail Press here.

For further information, please contact: dottie@rebeccacafiero.com

SOURCE: Landon Hail Press

View the original press release on ACCESS Newswire

• Policy Momentum: Federal and state policy alignment is accelerating nationwide SAF adoption

• Market Opportunity: U.S. SAF market projected at $7 billion by 2030, with a $25 billion global opportunity

• Strategic Investment: $350 million invested in the New Rise Reno facility, advancing America’s push to decarbonize aviation

HOUSTON, TEXAS / ACCESS Newswire / November 20, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Sustainable Aviation Fuel (“SAF”), today commented on the expanding policy momentum supporting SAF adoption across the United States.

Momentum is building fast. Under the U.S. SAF Grand Challenge, federal targets call for 3 billion gallons of annual production by 2030 – scaling to 35 billion gallons by 2050 to meet 100% of domestic demand. Today, production remains below 1% of U.S. jet fuel use, underscoring both the urgency and the scale of the opportunity.

The U.S. SAF market is expected to grow more than seven-fold – from approximately $860 million in 2024 to nearly $7 billion by 2030 – representing a compound annual growth rate (CAGR) of ~47%. Globally, the SAF market is projected to exceed $25 billion, with worldwide demand surpassing 5.5 billion gallons over the same period.

At the state level, momentum is accelerating in parallel. California, Oregon, Washington, and New Mexico have adopted low-carbon fuel standards that include SAF, and five additional states are advancing similar frameworks. Collectively, these states represent nearly 40% of total U.S. jet fuel consumption, creating a rapidly expanding incentive landscape for SAF deployment.

“Policy momentum is transforming aspiration into execution,” said Chris Cooper, CEO of XCF Global. “The U.S. is making it clear that sustainable aviation fuel is essential to the future of aviation. With supportive federal and state frameworks, airlines and energy companies can move beyond pilot programs and commit to long-term, scalable decarbonization strategies. At XCF, we’re building one of America’s leading SAF platforms – designed to scale production, strengthen domestic supply chains, and meet the growing demand for home-grown, low-carbon fuels.”

From inception, approximately $350 million has been invested in XCF’s flagship New Rise Reno facility. The company is advancing a project pipeline of three additional sites. The second facility, New Rise Reno 2, located adjacent to the existing site, will share utilities and logistics infrastructure to maximize efficiencies. XCF expects construction to begin in 2026 and operations from 2028, following an additional $300 million investment that is expected to double production capacity to ~80 million gallons per year.

As global demand accelerates, the U.S. has an opportunity to not only meet its own decarbonization goals but also to become a leading exporter of low-carbon fuels. Expanding domestic SAF production supports the Make More in America Initiative, creates high-tech, clean-energy jobs, and strengthens the nation’s competitiveness in the global energy transition.

“America’s aviation industry has always thrived on innovation,” Cooper continued. “With clear policy alignment and accelerating demand, the U.S. has a generational opportunity to lead the world in sustainable aviation. XCF is committed to turning that opportunity into action – transforming today’s policy commitments into tomorrow’s progress.”

About XCF Global, Inc.

XCF Global, Inc. is a pioneering sustainable aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. Our flagship facility, New Rise Reno, has a nameplate production capacity of 38 million gallons per year, positioning XCF as an early mover among large-scale SAF producers in North America. XCF is advancing a pipeline of three additional sites in Nevada, North Carolina, and Florida, and is building partnerships across the energy and transportation sectors to scale SAF globally. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~159.2 million; <20% free float (as of November 20, 2025).

To learn more, visit www.xcf.global.

Contacts:

XCF Global:
C/O Camarco
XCFGlobal@camarco.co.uk

Media:

Camarco
Andrew Archer | Rosie Driscoll | Violet Wilson
XCFGlobal@camarco.co.uk

Forward-Looking Statements

This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses, including manufacturing and operating expenses and interest expenses, as a result of potential inflationary pressures, changes in interest rates and other factors; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to regain compliance with Nasdaq’s continued listing standards and thereafter continue to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing to fund its operations and business plan and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) the New Rise Reno production facility’s ability to produce renewable diesel in commercial quantities without interruption during the ongoing SAF ramp-up process; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (11) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (12) payment of fees, expenses and other costs related to the completion of the Business Combination and the New Rise acquisitions; (13) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (14) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (15) changes in applicable laws or regulations; (16) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (17) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (18) the availability of tax credits and other federal, state or local government support; (19) risks relating to XCF Global’s and New Rise’s key intellectual property rights, including the possible infringement of their intellectual property rights by third parties; (20) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (21) the effects of increased costs associated with operating as a public company; and (22) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global made or will make with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

SOURCE: XCF Global, Inc.

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / November 20, 2025 / OMP, a global leader in supply chain planning solutions, brought together global supply chain executives, technology innovators, and strategic partners at the OMP REAL Conference 2025 in Miami. Held on November 18-19, the event showcased how agentic AI, decision-centric planning, and human-AI collaboration are reshaping the future of supply chain planning. A key highlight was UnisonIQ, OMP’s advanced AI orchestration framework, designed to support faster and smarter decisions across global supply chains.

Fortune 500 leaders share real-world transformation stories

Supply chain leaders from Arxada,AstraZeneca, Beiersdorf, Eastman, Johnson & Johnson, Kraft Heinz, Land O’Lakes, and Visy shared compelling case studies demonstrating tangible results:

• AstraZeneca outlined how they scaled Unison Planning™ across global operations, implementing decision-centric planning to improve agility and decision confidence in volatile markets.

• Beiersdorf revealed how AI-driven insights empower planners to make more informed, impactful decisions across their supply chain.

• Eastman showcased the integration of sustainability into core planning processes, demonstrating how they balance business performance with environmental goals.

• Participants from Kraft Heinz, Johnson & Johnson, and Land O’Lakes emphasized the growing importance of collaboration and shared innovation as companies work to make supply chains more resilient and adaptive.

Agentic AI takes center stage

Under the conference theme ‘REAL – Real expertise. Real solutions. Real results.‘, attendees explored how AI is transforming supply chain planning. Keynote speaker Kevin O’Marah, Co-Founder and Chief Research Officer at Zero100, delivered bold insights on how agentic and autonomous AI are transforming planner roles and redefining supply chain resilience.

The Unison Plaza served as an innovation hub where OMP experts showcased Unison Planning™, including UnisonIQ, the AI orchestration framework, and Unison Companion, its AI assistant. Live demos highlighted how AI-powered decision intelligence delivers always-on visibility, agility, and collaboration across end-to-end supply chains. Strategic alliance partners including Microsoft Azure, Rulex, Nulogy, EY, Deloitte, and Bluecrux showcased ecosystem innovations that accelerate digital transformation across industries.

A community united by progress

“Our customers are at the forefront of supply chain innovation,” said Paul Vanvuchelen, CEO at OMP. “Through human-AI synergy, they are redefining global supply chains with measurable impact across efficiency, service, and resilience. This conference brought our community together and reaffirmed our shared commitment to shaping the future of supply chain planning.”

About OMP

OMP helps companies facing complex planning challenges to excel, grow and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries – spanning consumer goods, life sciences, chemicals, metals, paper and packaging – benefit from using OMP’s unique Unison Planning™.

SOURCE: OMP

Related Images

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 20, 2025 / Most institutions didn’t build ahead of the new rules for global trade and its supply chains. They never expected any to emerge. So they built for what they knew best, an antiquated world where supply chains behaved predictably, certifications were trusted by default, and threats followed the familiar contours of physical borders.

The past few years shattered that illusion. Infiltrated materials, falsified documentation, unverifiable recycling claims, and foreign influence operations created vulnerabilities so deep that regulators had no choice but to rewrite the playbook. Governments and corporations are now reacting, scrambling to seal gaps they never expected to exist. SMX (NASDAQ:SMX) isn’t scrambling. SMX saw these fractures forming long before the market understood what they meant, and it built the one system designed to close every exposure these new rules have brought into the light.

Companies had time to stay ahead of the game. This shift in supply chain integrity didn’t happen in a single moment. It happened through accumulation, one breach layered onto another until the old assumptions finally collapsed. That’s the point where most organizations realized they were operating without the ability to authenticate the inputs flowing through their systems. They could monitor activity, but they could not confirm identity. They could measure output, but they could not prove origin.

SMX built its molecular identity platform before the blind spots became public weaknesses, creating a way for materials themselves to carry truth no matter how far they travel or how many times they change form. That’s the good news for everyone.

Countries Are Partnering Quickly in 2025

Singapore’s A*STAR is on board, selecting SMX to help build a national infrastructure for plastic circularity. This is a stark departure from the status quo. Countries like Singapore aren’t looking for more dashboards or better spreadsheets. They need real verification at the molecular level, full digital passports that hold up under pressure, and a financial system like the Plastic Cycle Token that assigns value to authenticated behavior rather than reported intentions. A*STAR recognized that SMX didn’t wait for regulations to force action. It built the infrastructure required to meet them the moment they arrived.

Industry after industry is now experiencing the same reckoning. Brands that once relied on loose certification frameworks-recycled plastics, natural rubber, textiles, electronics, luxury goods, semiconductors-have been pushed into a level of accountability they were never structurally designed to meet. They are retrofitting old processes to survive new expectations. SMX doesn’t retrofit. It embeds identity at the beginning of the chain, transforming compliance from an annual exercise into a living, persistent layer of truth.

This distinction matters. Monitoring tools track behavior after it happens. SMX verifies identity before it happens. Monitoring can be gamed, evaded, or manipulated. Molecular identity cannot. That is the line now dividing the companies prepared for the future from the ones still patching the past.

Not Just Material Products Like Gold, Textiles, and Rubber

National security agencies are arriving at the same realization. Modern infiltration isn’t defined by force; it’s defined by deception. The most damaging breaches don’t come through broken gates. They come through trusted doors. They come disguised as legitimate materials, credentials, certifications, and narratives that slip into environments assumed to be safe. Once inside, the damage is already done.

No worries for those paying attention. SMX closes that entry point. It authenticates every input, whether it is a shipment of metals, a recycled plastic bale, a computer processor or component, a precious metal bar, or a digital credential entering a system. It makes infiltration visible not after an incident but before it becomes one. And it does so in seconds, not days, weeks, or months, through a proprietary scanner designed for one purpose, to tell the truth.

Still, verification is just part of the SMX coverage. Its Plastic Cycle Token takes it to the next level. It’s not a speculative asset. It’s a value layer that emerges directly from verified material. Once authenticated, every unit of recycled plastic becomes a tradable, enforceable representation of real circularity. That changes compliance. It changes economics. And best of all, it changes how countries enforce environmental policy without crushing industry under impossible reporting burdens. SMX built this before regulators began the global shift toward enforcement. Now the world needs it.

And that is the point organizations must understand. The institutions acting now, including the six partnerships SMX secured so far in 2025, will lead the next era of supply-chain power. They will set the standards others follow, shaping the very definition of authenticity, accountability, and resilience. The ones who delay will spend years trying to retrofit systems that were never meant to withstand this level of scrutiny. They will face more than delay. They will face decay in brand perception, consumer trust, and regulatory pressure.

It’s No Secret… SMX Is Shouting the Answer

The message is no longer a secret. SMX is doing everything it can to shout from global rooftops that vulnerabilities are exposed and capable of causing catastrophic results. The grid, national security, counterfeiting, and defense systems are all at risk, not once in a while but 24/7/365.

It’s time for the world to pay attention to what SMX has been saying. The rules have changed. And the only way to win this new game is to be the leader who never gives up ground. SMX built the system that makes that possible.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This editorial contains forward-looking statements within the meaning of United States federal securities laws, and these statements are based on current expectations, assumptions, estimates, and projections regarding future events, business conditions, market dynamics, and the anticipated performance of SMX. Forward-looking statements are inherently uncertain and are not guarantees of future performance, and they involve known and unknown risks, uncertainties, and other factors that are difficult to predict and may be beyond the control of SMX. Actual results performance or achievements may differ materially from those expressed or implied in any forward looking statements due to a variety of factors including but not limited to changes in domestic or international regulatory requirements shifts in global supply chain conditions fluctuations in market acceptance and adoption of emerging verification technologies variations in economic or geopolitical environments competitive developments operational challenges in scaling new systems or partnerships and the ability of SMX to execute on its strategic initiatives commercial goals and research and development programs. Additional risks that could impact forward looking statements include changes in customer demand the timing and success of product deployments or pilot programs the availability of financing or capital resources industry wide disruptions shifts in sustainability reporting standards or auditing requirements evolving national security directives updates to environmental or materials traceability frameworks and the capacity of SMX to attract retain and collaborate with key partners governments corporations and research institutions. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect only the information and views available as of the date of publication and which may change as new events emerge or as underlying assumptions evolve. Except as required by applicable law, SMX undertakes no obligation to publicly update, revise, or supplement any forward-looking statements to reflect subsequent events, new information, or future circumstances, regardless of whether such changes arise from newly available data, subsequent developments or shifts in strategic direction

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

WEST PALM BEACH, FL / ACCESS Newswire / November 20, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been recognized for several prestigious international awards recognizing the brand’s excellence across sports, fashion, retail, media, and digital categories.

The globally celebrated, sport-inspired brand was named a double finalist at the 2025 Drapers Awards, one of the United Kingdom’s most respected fashion industry honors. U.S. Polo Assn. received the ‘International Excellence’ Award and was named a finalist in the ‘Menswear Brand of the Year’ category, acknowledging its remarkable growth and global retail performances across more than 190 countries. The Drapers Awards spotlighted brands, retailers, and designers shaping the future of the fashion industry, and celebrated with an elegant gala event at The HAC in London, England, on November 12, attended by Brand Machine, U.S. Polo Assn.’s strategic partner in the region. U.S. Polo Assn. won alongside other high-profile winners from the night, including Barbour, Primark, and Marks & Spencer, to name a few.

Additionally, U.S. Polo Assn.’s global magazine, Field X Fashion, Issue 2, has been shortlisted for “Best Use of Print” at the International Content Marketing Awards (ICMA), recognizing its creative storytelling and design excellence. The annual, global publication, presented by U.S. Polo Assn., showcases the intersection of sport, fashion, philanthropy, and influencer events through compelling photography, editorial features, and highlights from the 2025 global campaign that captures the essence of U.S. Polo Assn.’s 135-year heritage. The ICMA winners will be announced in January 2026.

Further demonstrating its growing digital influence, U.S. Polo Assn. has also received YouTube’s coveted Gold Creator Award for surpassing one million subscribers on the brand’s official channel. This milestone marks U.S. Polo Assn.’s commitment to engaging sports fans and consumers worldwide through high-quality video content, comprehensive global sports event coverage, and compelling brand storytelling.

Earlier in 2025, U.S. Polo Assn. was also honored across several respected global and regional award platforms for its creativity, innovation, and brand-building momentum. The brand earned two Stevie® International Business Awards, winning Gold for ‘Achievement in International Expansion’ and Silver for ‘Celebration Event’ for the 2024 Paris Games Polo Challenge. In India, one of the brand’s top global markets, U.S. Polo Assn. received multiple distinctions at top industry programs, including ‘Excellence in Marketing Campaign’ at the ET Now Business Conclave Awards, and two IReC Awards, ‘Video Marketing Masters’ and ‘Kids eRetailers of the Year.’ The brand additionally received recognition from Images Group for ‘Most Admired Marketing Campaign of the Year: Celebrity Endorsement’ for U.S. Polo Assn.’s Womenswear collaboration with Palak Tiwari.

“Being recognized across such diverse global awards platforms, from fashion and retail to sport and digital engagement, reinforces U.S. Polo Assn.’s authentic connection to sport, fashion, and storytelling,” said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. “These accolades are a testament to our Global Team and strategic partners who continue to elevate our brand through creativity, innovation, and purpose-driven growth.”

“We are incredibly proud of the many awards and recognitions that USPA Global and U.S. Polo Assn. have earned in 2025 and look forward to an award-winning 2026,” Prince added.

With more than 1,200 retail stores, 60-plus e-commerce sites in 20 languages, and distribution in over 190 countries, U.S. Polo Assn. continues to expand its global growth while maintaining its authentic connection to the sport of polo. Together, all the accolades underscore the brand’s continued worldwide strength and its ability to resonate with consumers through compelling storytelling, strategic marketing, and consistent retail expansion, making it one of the world’s most dynamic and accessible sports brands.

Photo Captions:

1. U.S. Polo Assn./Brand Machine U.K. Team, Daniel Windross (L), Mathew Guinchard (M), Boo Jalil (R), accepting the Drapers Award for ‘International Excellence’ at the Awards Ceremony at The HAC in London, England

2. U.S. Polo Assn. Awarded ‘International Excellence’ at the 2025 Drapers Awards

About U.S. Polo Assn. and USPA Global

U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.

U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.

For more information, visit uspoloassnglobal.com and follow @uspoloassn.

USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.

###

Contact Information

Stacey Kovalsky
VP, Global PR and Communications
skovalsky@uspagl.com
+001.561.790.8036

Kaela Drake
PR & Communications Specialist
kdrake@uspagl.com
+001.561.461.8596

SOURCE: U.S. Polo Assn.

Related Images

View the original press release on ACCESS Newswire

New handheld payments and ordering device combines full POS functionality, payment acceptance, and business management tools in one powerful, standalone solution for American entrepreneurs.

BOULDER, CO / ACCESS Newswire / November 20, 2025 / SumUp, the financial technology company dedicated to empowering small merchants, today announces the U.S. launch of its new SumUp Terminal, an all-in-one, handheld device that brings together full Point of Sale (POS) functionality, fast payment acceptance, and essential business management tools in a sleek, mobile device.

Built for day-to-day realities of running a small business, the Terminal removes the need for bulky setups or a connected smartphone. It operates independently with Wi-Fi or its built-in cellular connection (eSIM card included), a key differentiator that ensures reliable, on-the-go functionality wherever business happens.

The SumUp Terminal runs the powerful SumUp SuperApp, giving entrepreneurs access to everything they need to run their business:

• Accept Payments Anywhere: Process tap, dip, or swipe transactions with affordable and transparent pricing at 2.6% + 10¢ for all card-present payments. The device features long-lasting battery life for full-day operation and reliable connectivity with built-in 4G and Wi-Fi backup.

• Streamline Operations: The intuitive touchscreen and larger display enable complex features like table management, easy item catalog management, and seamless order taking-all from the palm of your hand. It also includes an integrated receipt printer for instant printed receipts.

• Manage Your Business: Use the device as a comprehensive business hub to manage item catalogs, track sales and inventory in real-time, generate detailed reports for simplified bookkeeping, and create staff profiles with customized access levels.

• Durable and Secure: Built with durability in mind, the Terminal features Corning® Gorilla® Glass 5 for extra protection, a barcode scanner, and AI-powered image recognition to quickly snap, scan, and add products.

“Small businesses need tools that are dependable, flexible and simple to use,” said Andrew Helms, CEO of SumUp USA. “The U.S. market demands solutions that offer both professional-grade power and the utmost flexibility, without the prohibitive cost and complexity of legacy systems. The SumUp Terminal brings payment acceptance and key business features together in a single device, making it easier for merchants to stay organized and serve customers wherever they are.”

SumUp is offering a 10% discount on the Terminal until November 23, 2025. This will be followed by a Black Friday/Cyber Monday promotion offering 25% off all readers from November 24, 2025, to December 1, 2025. For more information, click here.

About SumUp

SumUp is a global financial technology company driven by the mission of empowering small businesses all over the world. Established in 2012, SumUp is the financial partner for more than 4 million entrepreneurs in over 35 markets worldwide. In the United States, SumUp offers an ecosystem of affordable, easy-to-use financial products, such as point-of-sale and loyalty solutions, card readers, and invoicing.

For more information, please visit https://www.sumup.com

SOURCE: SumUp

View the original press release on ACCESS Newswire

Crofelemer can potentially extend lives of MVID patients – infants and children who face the lethal natural history of the disease

Parenteral support reduction of up to 37% is groundbreaking; No approved treatments exist for MVID in any region

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 20, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, in support of a possible expedited approval pathway for crofelemer for treatment of intestinal failure in patients with the ultrarare genetic disorder microvillus inclusion disease (MVID), the company has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for the company’s ongoing placebo-controlled clinical trial of crofelemer in pediatric MVID patients.

MVID patients are born without the ability to absorb the basic nutrients of life, and are therefore subject to a lethal natural history and a lifetime of parenteral support which is associated with toxicities and comorbidities. The ability of crofelemer to decrease the volume of parenteral support is potentially life extending for these patients and is thus disease progression modifying. Crofelemer provides an opportunity for improved quality of life, potentially reducing the time MVID patients spend on parenteral nutrition and/or supplemental intravenous fluids by up to 37% a day from what is often up to 20 hours a day, 7 days a week to support the daily electrolyte and nutrient needs of the patient.

“In light of the initial groundbreaking results of the investigator-initiated trial (IIT) of crofelemer in the United Arab Emirates for treatment of MVID and in support of our efforts to make crofelemer available to children with MVID as quickly and efficiently as possible, as announced, the company met with the FDA on October 2, 2025 to seek their advice regarding our ongoing clinical trial of crofelemer for MVID treatment. Based on the feedback from the FDA during this meeting, we have proposed an amendment to our protocol for this study and submitted the amended protocol to the FDA for their review. Our expectation is that the amended protocol, along with the results of this study, if positive, will support a faster FDA review and approval of crofelemer for MVID,” said Pravin Chaturvedi, PhD, Jaguar’s Chief Scientific Officer and Chair of the Jaguar and Napo Scientific Advisory Board.

Jaguar has also discussed the potential for approval of crofelemer for MVID with the European Medicines Agency, the EU’s equivalent of the FDA, based on a study in potentially a small number of patients given the burden of MVID. “That’s how unprecedented crofelemer’s mechanism of action and these results are in intestinal failure patients with MVID,” said Lisa Conte, Jaguar’s founder, president, and CEO. “MVID is a devastating ultrarare pediatric disorder, with an estimated worldwide prevalence of only 100-200 patients, so a trial of crofelemer in just a small number of MVID patients is expected to be statistically meaningful.”

As presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, the initial groundbreaking results of an ongoing and independent IIT of crofelemer in the UAE for treatment of pediatric intestinal failure, which includes patients with intestinal failure due to MVID and short bowel syndrome (SBS-IF), demonstrate disease progression modification through reduction of total parenteral support (PS) in pediatric intestinal failure patients that ranged from 12 to 37%. For the initial MVID patient who has completed treatment, PS needs were reduced by up to 27% at the highest dose over the initial 12-week treatment period and up to 37% during the extension period upon reinitiation of crofelemer treatment, and also showed reduced frequency of loose watery stools. This finding supports continued evaluation of crofelemer to reduce PS needs for pediatric MVID patients.

MVID causes intestinal failure, a situation where the patient’s intestines are unable to absorb the fluids, electrolytes and nutrients required to survive and thrive. Intestinal failure is a debilitating, morbid and lifelong condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute parenteral support (PS). Most intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for these patients, PS is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, liver and kidney function problems – as well as a risk of neurodevelopmental delay. These symptoms may emerge at any time in intestinal failure patients, and often become life-threatening.

In addition to supporting the IIT in the UAE and conducting the placebo-controlled clinical trial of crofelemer in pediatric MVID patients at sites in the U.S., E.U., and Middle East, the company is also providing crofelemer powder for oral solution for use in two expanded access programs in the U.S. to treat intestinal failure in pediatric patients with MVID.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the amended protocol the company submitted to the FDA for the company’s ongoing trial of crofelemer for the treatment of intestinal failure in MVID patients will support a possible expedited approval pathway for crofelemer for this indication, Jaguar’s expectation that the ability of crofelemer to decrease the volume of PS is life extending and disease progression modifying for MVID patients, and that crofelemer provides an opportunity for improved quality of life for MVID patients by reducing the time MVID patients spend on parenteral nutrition and/or supplemental intravenous fluids by up to 37% a day, Jaguar’s expectation that the amended protocol, along with the results of the company’s study, if positive, will support a faster FDA review and approval of crofelemer for treatment of MVID, and Jaguar’s expectation that crofelemer could also be approved by the European Medicines Agency for MVID based on a study in potentially a small number of patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission and acceptance of the end-of-phase 1 meeting package to FDA and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).

“The Revelation team has worked tirelessly on our end-of-phase 1 meeting submission, and we look forward to our FDA meeting scheduled for later this year,” said James Rolke, Chief Executive Officer of Revelation. “Our near-term focus will be conducting the necessary activities for initiating and running a later stage clinical study during 2026 to evaluate the ability of Gemini to effectively treat AKI. In addition, we plan to publish additional positive results from the PRIME study that completed this year and to expand potential uses of Gemini for other conditions through preclinical and clinical testing.”

Revelation recently announced positive safety and activity data from its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met. In addition, the potential of Gemini to treat acute and chronic inflammatory conditions was demonstrated by significantly reducing inflammatory activity and restoring normal cellular response to stimuli at the cellular level, as measured in peripheral blood mononuclear cells (PBMCs) isolated from patients at predose, 2, 24, and 168 hours post-dose.

About the PRIME Study

The PRIME study enrolled 40 patients from 32 to 78 years of age, at 3 US-based clinics specializing in the care of patients with CKD. A total of 5 cohorts (8 per cohort, 6 treated/2 placebo) at 4 dose levels were enrolled: a subtherapeutic dose, a low dose, the target dose (cohorts 3 and 4), and a high dose. Additionally, an extension protocol was conducted to collect PBMC and biomarker samples in 8 Gemini naive or secondary naive patients. The primary endpoint evaluation of safety was met. Patient PBMCs were isolated predose and at 2, 24, and 168 hours post-dose. PBMCs were analyzed ex vivo for background inflammation by measurement of IL-1β, TNF-α, IL-6, IL-10, and IL‑1RA. Cells were also assessed for response to stimulation by lipopolysaccharide (LPS, also known as endotoxin) or high mobility group box-1 protein (HMGB1). Subgroup analysis divided patients into two categories, those with PBMCs of minimal background inflammation activity (40 pg/mL IL-1β) and normal response to stimuli, and those with significant background inflammation activity (>40 pg/mL IL-1β). Approximately 50% of patients were in each group.

In patients with high background PBMC activity, Gemini significantly reduced inflammation relative to placebo patient PBMCs at all time-points post dose (IL-1β: p<0.01, IL-6: p<0.01, TNF-α: p=0.05, IL-10: p<0.01, IL-1RA: p<0.001). Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects. In addition, Gemini was able to demonstrate correction of the immunoparalysis typical to chronic disease. Gemini significantly increased the responsiveness to LPS stimulation in high background patient PBMCs relative to placebo at all timepoints (IL-1β: p<0.0001, IL-6: p<0.0002, TNF-α: p<0.002, IL-10: p=0.09, IL-1RA: p<0.01). Gemini also significantly increased the responsiveness of patient PBMCs with high background vs placebo patient PBMCs with high background at all time-points to HMGB1 stimulation (IL-1β: p<0.05, IL-6: p<0.01, TNF-α: p<0.01, IL-10: p<0.05, IL-1RA: p<0.002). The increased responsiveness was comparable to PBMCs isolated from healthy subjects. These results show the ability of Gemini to salvage the normal inflammatory response, even as far as one week after a single dose. For the low background patients, as expected, Gemini does not increase inflammatory activity. Additional analysis on the effect of LPS or HMGB-1 stimulation is ongoing.

Revelation will seek to publish these results and those from ongoing additional data analysis. For more information on Revelation, please visit www.RevBiosciences.com.

About AKI

Acute Kidney Injury or AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease and death.

AKI is a major cause of morbidity and mortality, affecting more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units. Renal replacement therapy (dialysis) is still the only therapeutic option in the treatment of the consequences of severe AKI and is required in approximately 20% of all critically ill patients. Despite the fact that these patients show high mortality rates, up to 40% of patients who survive such an episode have develop chronic kidney disease or end-stage renal disease. As such, new therapies to treat AKI are currently needed.

About Gemini

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD^®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEMINI-AKI program). Gemini is also being developed as a treatment for chronic kidney disease (GEMINI-CKD program), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI) and as a treatment to prevent post-surgical infection (GEMINI-PSI program). The potential of Gemini has been demonstrated in multiple preclinical models of AKI, CKD and infection, as well as in two phase 1 clinical studies. See additional detail here.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

University of Louisville Health pilots tool to tackle capacity constraints and improve patient flow across its system

PITTSBURGH, PA / ACCESS Newswire / November 20, 2025 / TeleTracking Technologies, the market leader in healthcare operations platforms for hospitals and health systems, today announced the launch of Decision IQ, the first AI-driven solution designed to manage patient flow at scale, during its annual TeleSummit customer conference in Nashville. The solution is already in place at University of Louisville Health (UofL Health), where leaders are using it to address capacity constraints and improve access.

Hospitals have long struggled to manage patient throughput – balancing incoming demand with limited space, staff, and resources – while relying on retrospective data that only shows what has already happened. Decision IQ replaces that model with proactive, system-wide visibility that empowers users to plan ahead and act in real time. At its core, Decision IQ is an AI-driven computational twin that unifies data from every department and ancillary service, creating a dynamic, system-wide view of patient movement. The technology simulates discharge priorities, predicts capacity needs, and translates those insights into clear direction within existing workflows to help care teams anticipate challenges before they escalate and reduce manual coordination so clinicians can focus more on patients.

“Decision IQ is about taking throughput data and making it actionable,” said Christopher Johnson, Co-CEO, TeleTracking. “By surfacing potential issues before they arise and recommending adjustments across the system, leaders gain the foresight to mitigate bottlenecks in advance – ensuring patients remain at the center of operational decisions. This marks a true transformation in how hospitals manage operations in the age of AI.”

UofL Health decided to implement Decision IQ after confronting growing capacity pressures and their impact on patient safety and care. As an early adopter, UofL saw the opportunity to apply AI to one of healthcare’s most persistent challenges – patient flow – and expand its longstanding partnership with TeleTracking beyond transfer operations.

“Our teams work tirelessly to move patients safely and efficiently, but traditional processes made it difficult to stay ahead of daily demand,” said Deanna Parker, MBA, MHA, BSN, RN, VP, Chief Nurse Executive, Downtown UofL Health. “Decision IQ gives us a forward-looking view of our operations, helping us anticipate where throughput challenges will occur and coordinate across departments before they impact patient care.”

About TeleTracking

TeleTracking is a technology company and the global leader in healthcare Operations Platforms, helping hospitals and health systems optimize patient flow, capacity, staffing workflows, and performance across clinical and operational domains. With over 35 years of experience, TeleTracking combines domain expertise with operational solutions that seamlessly integrate with EMRs and other enterprise systems, extending operational visibility across entire networks. Learn more at teletracking.com.

Media Contact:
Karina Stabile
Aria Marketing for TeleTracking
kstabile@ariamarketing.com
(516) 317-5835

SOURCE: TeleTracking

View the original press release on ACCESS Newswire

The acclaimed television series will highlight how LegalEASE is setting a new standard in legal benefits through innovation, education, and a national network of top-tier attorneys.

HOUSTON, TEXAS / ACCESS Newswire / November 20, 2025 / LegalEASE, a leading provider of legal insurance benefits for employers and organizations across the United States, will be featured on an upcoming episode of “Trending Today,” airing on Fox Business on November 23rd at 5:30 pm est. LegalEASE will also be spotlighted on the Trending Today Podcast, giving viewers and listeners an inside look at how the company is modernizing legal benefits and making high-quality legal support more accessible than ever.

“Trending Today” explores innovation across technology, health and wellness, consumer products, and business services-featuring companies that are elevating industries and transforming lives. LegalEASE stands out for its mission-driven approach: providing indispensable legal protection and education to employees at companies of all sizes.

With more than 50 years of experience and a nationwide network of credentialed attorneys, LegalEASE offers benefit plans that help employees navigate life’s biggest challenges-from real estate transactions and family law to identity theft protection, estate planning, financial disputes, and more. Their personalized matching system, hands-on guidance, and robust support tools make it easier for individuals to understand their options with confidence.

At the helm of LegalEASE is Bob Heston, the company’s CEO and the driving force behind its innovation. A recognized pioneer in the legal benefits industry, Heston has spent decades redefining how individuals access and understand legal support. His visionary approach, centered on education, empowerment, and exceptional service, has shaped LegalEASE into one of the most respected legal benefits providers in the country. Under his leadership, the company continues to expand its network, elevate service standards, and introduce groundbreaking solutions that simplify the legal process for employees and their families.

“At Trending Today, we highlight companies that empower people to live better, more secure lives,” said Liz Plummer, executive producer of Trending Today. “LegalEASE impressed our team with its commitment to education, personalized legal support, and its innovative approach to connecting employees with vetted attorneys. Their story represents the type of forward-thinking service that’s transforming the modern benefits landscape.”

 Viewers will learn how LegalEASE is taking the confusion and intimidation out of hiring legal help by offering easy onboarding, expert guidance, and curated legal resources. Through its Legal Access Plans and nationwide attorney networks, the company delivers a seamless experience that saves employees time, money, and stress-especially during life’s most difficult moments. Whether individuals are buying a home, starting a family, facing disputes, or navigating the unexpected, LegalEASE supports them with clarity and care.

“Our goal is simple: make legal protection a practical, accessible resource for every employee,” said Jason Weekley for LegalEASE. “We believe that legal benefits should offer more than coverage-they should offer guidance, reassurance, and a trusted path forward. Being featured on Trending Today allows us to share how we’re reshaping the way people access legal services.”

For more than 13 years, “Trending Today” has showcased industry leaders and innovators across technology, consumer products, luxury lifestyles, and business services. The award-winning series continues to shine a spotlight on organizations that are pushing boundaries and redefining what’s possible.

About ‘Trending Today’
Trending Today, the acclaimed television series airing on A&E, Bloomberg, and Fox Business, captures the entrepreneurial ambition that drives innovation around the world. Each episode highlights the latest technologies, market trends, and groundbreaking ideas through a thoughtfully curated lineup of inventors, innovators, and thought leaders. Spanning industries such as consumer products, luxury lifestyles, health, and technology, Trending Today features companies and leaders who are pushing boundaries and redefining excellence. To learn more, visit www.trendingtoday.com.

About LegalEASE
LegalEASE, a trusted leader in legal benefits for more than 50 years, provides organizations and their employees with comprehensive legal protection through expertly designed Legal Access Plans. With a nationwide network of credentialed attorneys and a proprietary matching system, LegalEASE connects individuals with the right legal experts for matters ranging from real estate and family law to identity theft, estate planning, financial disputes, and more. The company is dedicated to making legal support accessible, affordable, and easy to understand through personalized guidance, educational tools, and hands-on service. LegalEASE empowers employees to navigate life’s most important moments with confidence and clarity. To learn more, visit www.legaleaseplan.com.

Media Contacts:
Jason Weekley
jason_weekley@legaleaseplan.com

 Liz Plummer
Liz@trendingtoday.com

SOURCE: Trending Today

View the original press release on ACCESS Newswire